Lyophilization may be considered a relatively gentle drying
process, but there are still risks and pitfalls when applying it to biomolecular
reagents in diagnostic tests that are different to the freeze-drying of general
pharmaceuticals. Reagents typically used in ELISA and PCR based diagnostic kits
for diseases, such as COVID-19 tend to contain labile components, such as
enzymes that need preserving for longevity in the supply chain or antibodies to
test for a patient’s response to the virus, which can be challenging to
stabilize for commercial use.
This webinar explores various aspects of formulation and
cycle development for diagnostic reagents relevant to COVID-19, including the
design/selection of container-closure systems and the selection of appropriate
equipment.
Please find the link of webinar below:
Please feel free to contact us for more details.
Leave a Comment